If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
172
results.
Updated on
27/07/2026 [08:08:00]
Results 125 to 150 of 172
Absstract of: US20260158171A1
The disclosure provides insulin-glucagon-like peptide 1 (GLP-1) polynucleotides for delivery to pancreatic islet cells, as well as compositions comprising the polynucleotides and methods of treating obesity-associated metabolic disorders.
Absstract of: US20260157662A1
The device for dynamic determination of a slow insulin dose to be injected comprises: a means (21) of acquiring multiple blood glucose levels during a first day and the day following the first day,a means (26) of calculating the difference in blood glucose levels,a means (22, 24, 25, 42, 43) of determining if a predetermined event has occurred between going to bed and getting up,a means (26) of determining, if no predetermined event has occurred, a hyperglycaemia or a hypoglycaemia depending on the difference in blood glucose levels,a means (26) of determining if at least a predetermined number of hyperglycaemias or hypoglycaemias have occurred in a predetermined period of time,a means (26) of modifying the slow insulin to be injected, in this case of an occurrence, anda means (25) of indicating a numerical value of the modified slow insulin dose to be injected.
Absstract of: US20260159864A1
0000 A standardized plant extract is produced by cultivating undifferentiated or differentiated in vitro cultures of Haberlea rhodopensis Friv. (HR), followed by harvesting the biomass and extracting bioactive compounds and primary and secondary metabolites, including organic acids, fatty acids, amino acids, sterols, free phenols, sugars, and polyphenols. The extraction process is performed under controlled conditions to yield an extract with a predominant myconoside content of 70% to 96% in the polyphenolic fraction, constituting 18% to 35% of the total extract. The extract may be combined with glycerol to form a composition with standardized myconoside content. The resulting extract or biomass is then incorporated into products for the pharmaceutical, cosmetic, or food industries. This method provides a consistent, renewable, and sustainable source of raw material, eliminating dependence on wild plant populations and seasonality, and delivers valuable health-protective properties.
Absstract of: WO2026120569A1
A system includes a wearable device and a charger case. The wearable device is configured to be positioned on an ear of a wearer, and includes first and second body portions and a connection member mechanically coupled to each of the first body portion and the second body portion. The first body portion and/or the second body portion includes a processor, a memory, and a sensor set including at least one of a pulse oximeter, a photoplethysmogram (PPG) sensor, an accelerometer, a temperature sensor, a proximity sensor, an ambient light sensor, or a gyroscopic sensor. The memory stores instructions to cause the processor to calculate at least one of a blood oxygen saturation level, a pulse rate, a blood pressure level, a blood flow rate, a cardiac output/rhythm, a blood sugar level, a blood carbon monoxide level, a blood nitrous oxide level, or an electrocardiogram of the wearer.
Absstract of: WO2026120503A1
The technology provides a system and method for assessing loss of vibration perception in a subject. It may be useful for the self-diagnosis, self-monitoring and self-treatment of adverse health conditions such as cutaneous neuropathy or diabetic foot, and for developing related prognoses. The system comprises a wearable or handheld vibration device which includes piezoelectric elements. These may be actuated to produce vibrations which are transmitted to the body surface of the subject by a probe. A communications apparatus is provided so that data can be transferred between the vibration device and a computing device such as a smartphone. The computing device is arranged to control levels of intensity of vibration of the piezoelectric elements, to record data representing levels of intensity of vibration, and to record and track input data entered by the user, corresponding to levels of intensity of vibration at which the subject perceives the transmitted vibrations via their body surface.
Absstract of: US20260157664A1
The blood glucose measuring device includes a processor and a memory storing instructions, wherein the instructions, when executed by the processor, cause the blood glucose measuring device to obtain, via a first receiver, a plurality of reflection signals, which is a plurality of lights output from the light source, and obtain, via a second receiver, a plurality of transmission signals, determine, for each of the plurality of reflection signals and each of the plurality of transmission signals, a slope efficiency, which represents a ratio of an output change to an input change of the blood glucose measuring device, determine first analysis data based on the slope efficiency of the plurality of reflection signals and/or second analysis data based on the slope efficiency of the plurality of transmission signals, and determine a final blood glucose value based on at least one of the first analysis data or the second analysis data.
Absstract of: WO2026119866A1
The present invention relates to a computer-implemented method for predicting a risk for a subject to experience an analyte concentration in a bodily fluid above a predetermined glucose event threshold at the end of a predetermined predicting time interval, a data processing system, a computer program, a system, and remote control. The disclosure, thus, relates to the management of diabetes. The risk is predicted based on a plurality of input parameters and using a machine learning model.
Absstract of: US20260158217A1
A diabetes management system including a wearable device having an elongated support patch with an adhesive disposed on a skin side, a sensor portion disposed on a non-skin side and including an electrochemical glucose sensor and a wireless communication module, and a medication delivery portion disposed on a non-skin side and comprising a medication reservoir and a medication pump. The system also includes a behavior tracking device having a tracking wireless communication module, a portable electronic device configured to communicate wirelessly to the wearable device and the behavior tracking device, and a controller. The sensor portion is configured to detect a glucose level of a subject and the controller is configured to receive the glucose level and to transmit to the medication pump an instruction which causes the medication pump to deliver a dose to the subject of a medication based on the glucose level.
Absstract of: US20260157702A1
0000 Control device (30) for determining an amount of carbohydrate (RC) recommendation. The control device comprises a retrieving unit (32), the retrieving unit (32) being configured to retrieve user data, an outlier unit (34), the outlier unit (34) being configured to determine whether a user data is considered to be an outlier or not, an RC unit (36), the RC unit (36) being configured to estimate an RC recommendation using mathematical functions of the user data; and a transmission unit (38), the transmission unit (38) being configured to transmit the RC recommendation. The transmission unit (38) is configured to transmit the RC recommendation if and only if the last user data is not considered to be an outlier.
Absstract of: WO2025029671A1
Disclosed herein are methods of treating a subject having diabetes with a population of cells expressing ISL1 and one or more immunosuppressive reagents, such as an anti-thymocyte globulin binding moiety.
Absstract of: US2025049355A1
Certain aspects of the present disclosure provide a monitoring system comprising a continuous analyte sensor configured to penetrate a skin of a patient and generate a sensor current indicative of analyte levels of the patient, and a sensor electronics module coupled to the continuous analyte sensor. The sensor electronics module comprises an analog to digital converter configured to receive the sensor and convert the sensor current generated by the continuous analyte sensor into digital signals, one or more processors configured to convert the digital signals to a set of analyte measurements indicative of the analyte levels of the patient, and a Bluetooth antenna configured to transmit the set of analyte measurements wirelessly to a wireless communications device using Bluetooth or BLE communications protocols.
Absstract of: EP4756833A1
The invention discloses a diabetes management system for use in a hospital, including: at least a wearable medical device, a plurality of receivers, a central server and a healthcare provider terminal, the receivers receive the data information transmitted by the medical device and upload it to the central server, and the healthcare provider communicates with the central server and displays or reviews the medical data information through the terminal, as any one of the multiple receivers can receive the data information transmitted by the medical device and upload it to the central server, as a result, the patient's range of motion in the hospital is no longer restricted, which improves the patient's experience and keeps the patient in a comfortable mood, while the healthcare provider is able to know the patient's blood glucose level and/or insulin infusion state in real time through the healthcare provider terminal and deal with the abnormalities in a timely manner, so that the patient's blood glucose level can be maintained at a stable level.
Absstract of: EP3831293A1
The present disclosure relates to a continuous blood glucose measurement body attachment unit, and provides a continuous blood glucose measurement body attachment unit, which is manufactured in an assembled state in an applicator so as to minimize separate additional operations, such that the body attachment unit can be attached to the body with only a simple operation of the applicator and, particularly, the body attachment unit has a wireless communication chip so as to be capable of communicating with an external terminal, thereby enabling simple and convenient usage without an additional operation in which a separate transmitter must be connected and enabling maintenance to be more easily performed, and after the body attachment unit is attached to the body, an operation starts by the control of a user, such that an operation start time point can be adjusted to an appropriate time point according to the needs of the user, and an operation can start in a stabilized state, such that blood glucose can be more accurately measured.
Absstract of: WO2026116775A1
Disclosed is a blood glucose measurement device capable of improving blood glucose measurement accuracy by focusing rays of light for blood glucose measurement in the measurement area of an object. According to an embodiment of the present invention, the blood glucose measurement device comprises: a light source unit disposed to output a plurality of first light rays for measuring blood glucose in the measurement area of an object; an optical unit including one or more optical bodies disposed to emit a plurality of first light rays toward the measurement area of the object; and a light-receiving unit disposed to receive a plurality of second light rays output through an interaction between the plurality of first light rays and the object. The one or more optical bodies include: a plurality of lenses arranged to condense a plurality of first light rays on the first surface of one or more optical bodies facing the light source unit; a reflective surface arranged to reflect a plurality of first light rays condensed by the plurality of lenses on the second surface of one or more optical bodies; and a refractive surface arranged to refract a plurality of first light rays reflected at the reflective surface toward the measurement area of the object on the third surface of one or more optical bodies.
Absstract of: WO2026114687A1
A method for identifying a deviation of a first biomarker measurement, comprising: receiving a first biomarker measurement from a subject at a first timepoint; comparing the received first biomarker measurement to a subject-determined baseline of first biomarker measurements; determining, based on the comparison, that the first biomarker measurement is a deviation from the subject-determined baseline of first biomarker measurements; and reporting the determined deviation of the first biomarker measurement.
Absstract of: WO2026114787A1
A method (100) for adjusting a first biomarker measurement, comprising: receiving (120) a first biomarker measurement from a subject; contemporaneously receiving (130) a time-dependent biomarker measurement from the subject; comparing (140) the time-dependent biomarker measurement to a subject-determined baseline; determining (150), based on the comparison, a time-warp of a baseline first biomarker measurement; and adjusting (160) the baseline first biomarker measurement by the determined amount of the time-warp to generate an adjusted first biomarker measurement.
Absstract of: WO2026114257A1
The present invention relates to a fusion protein and the use thereof. Specifically, provided in the present invention are a GCGR-IgG2/Fc fusion protein, a polynucleotide encoding the fusion protein, a vector and cell comprising the polynucleotide, and a composition thereof. The present invention also relates to the use of the fusion protein, polynucleotide, vector, cell and composition in a drug, and/or in the preparation of a drug for treating or preventing a glucose metabolism-related disease.
Absstract of: US20260151570A1
A method may include displaying at least three icons on a user interface of a mobile device, including a first icon associated with the at least three icons associated with a first carbohydrate level, a second icon associated with the at least three icons associated with a second carbohydrate level, and a third icon associated with the at least three icons associated with a third carbohydrate level. The method may also include receiving a user selection of one of the three icons through the user interface of the mobile device, and determining an insulin bolus level from the user selection. The method may also include communicating the insulin bolus level to an insulin delivery device.
Absstract of: US20260151572A1
Systems and methods are provided for a dual needle apparatus configured to couple to a reservoir of a syringe assembly with a luer lock fitting. The dual needle apparatus may include at least a first needle and a second needle, the first needle longer than the second needle. The first needle may be configured to deliver insulin from the reservoir to the interior of a medication bladder when inserted into the medication bladder. The second needle may be configured to release air or insulin from the medication bladder to an external environment responsive the pressure caused by insulin delivery through the first needle.
Absstract of: US20260151059A1
Analyte sensor apparatus, systems, and methods to reduce sensor drift. An analyte sensor apparatus (102) for detecting an analyte such as glucose in a target environment (10) such as a body tissue may include a plurality of electrodes and a controller. The plurality of electrodes may provide a plurality of electrode signals based on the target environment while disposed in the target environment. The controller may be operatively coupled to the plurality of electrodes and configured to receive the plurality of electrode signals. The controller may further be configured to adjust a voltage of at least one electrode of the plurality of electrodes based on a voltage profile to regenerate one or more electrodes of the plurality of electrodes while the at least one electrode is disposed in the target environment. This may allow to correct an electrode drift without removing the electrode from its target environment.
Absstract of: US20260151565A1
The exemplary embodiments provide an automated approach for adjusting the medicament delivery rate to the user when operating in an open loop manner (“open mode”). The approach relies upon an insulin delivery history to the user make adjustments to the medicament delivery rate in the open mode. In particular, the exemplary embodiments may look at the medicament delivery history while the medicament delivery device is operating in a closed loop manner (“closed mode”) to determine how to adjust the open mode medicament delivery rate. It is presumed that in closed mode, the control system of the medicament device has gained knowledge over time about how to control the medicament delivery rate to produce good treatment outcomes for the user. The exemplary embodiments leverage this knowledge to adjust the open mode medicament delivery rates. Medicament bolus deliveries in open mode may also be adjusted in like fashion.
Absstract of: US20260151056A1
0000 Techniques disclosed herein relate to calibrating glucose values. In some embodiments, the techniques may involve measuring one or more calibration values of an operating parameter of one or more monitor electrodes. The techniques may further involve determining one or more delta values using the one or more calibration values and one or more pre-calibration values, wherein the one or more delta values are indicative of a first reaction of a first chemistry stack of the one or more monitor electrodes. The techniques may further involve utilizing a relationship between a second reaction of a second chemistry stack disposed on one or more working electrodes and a first reaction of the first chemistry stack to translate the one or more delta values associated with the operating parameter of the one or more monitor electrodes to a change in an operating parameter of one or more working electrodes.
Absstract of: WO2025021960A1
The present invention relates to a biosensor for measuring the concentration of glucose and its use in glucose sensing. The biosensor of the present invention comprises a polymer comprising a boronic acid-based glucose-binding moiety, wherein said boronic acid-based glucose-binding moiety is immobilized in said polymer, and an inhibitor moiety, wherein said inhibitor moiety is immobilized in said polymer, and wherein said inhibitor moiety is capable of forming reversible crosslinks by binding to said boronic acid-based glucose-binding moiety. In the absence of glucose, the polymer is crosslinked by a bond formed between the boronic acid-based glucose-binding moiety and the inhibitor moiety. In the presence of glucose, the boronic acid-based glucose-binding moiety binds to glucose, whereby the bond between the boronic acid-based glucose-binding moiety and the inhibitor moiety is broken, which results in a change of volume of the polymer. The biosensor of the present invention is particularly useful for glucose monitoring performed on a subject under intensive care as well as in the situations wherein the glucose monitoring is performed on an unconscious subject.
Absstract of: WO2025021930A1
The present invention relates to a biosensor for measuring the concentration of glucose and its use in glucose sensing, wherein the biosensor comprising a polymer comprising the moiety of formula (I). The biosensor of the present invention is particularly useful for glucose monitoring performed on a subject under intensive care as well as in the situations wherein the glucose monitoring is performed on an unconscious subject.
Nº publicación: RS68035B1 29/05/2026
Applicant:
JANSSEN BIOTECH INC [US]
JANSSEN BIOTECH, INC.
Absstract of: CA2860107A1
The present invention provides methods to promote the differentiation of pluripotent stem cells. In particular, the present invention provides methods to produce a population of cells, wherein greater than 10% of the cells in the population express markers characteristic of single hormonal pancreatic beta cells.
BOPI
Electronic site
